Understanding requires analyzing. The aim of our research is to decipher the molecular mechanisms controlling glycemia, lipidemia and heart remodeling. The corresponding findings will ensure the identification of novel biomarkers to predict, diagnose and classify as well as to validate nutritional and pharmacological therapeutic strategies for the control of diabetes, dyslipidemia and obesity as well as their co-morbidities such as heart failure and liver fibrosis.
We have been among the first to identify the role and novel mode of action of intestinal functions: the role of incretin secretion on the autonomic nervous system (gut brain periphery axis), the molecular handling of gut lipids, and intestinal immune defense. In addition, we evidenced the role of gut and mouth microbiota on the oral and intestinal adaptive and innate immune defense for the control of the translocation of bacteria and bacterial factors (metafactors) towards the tissues of the host to establish an internal tissue microbiota. The latter controls the tissue transcriptom and initiates metabolic inflammation for the development of metabolic diseases and heart remodeling.
These major scientific steps have been performed thanks to the development of innovative processes suitable for the physiological phenotyping of animal models, mathematical models, and original and unique animal models which enable us to generate novel molecular hypotheses and to validate their relevance. Eventually, thanks to close national and international collaborations with clinicians from our group we set up original data bases and clinical trials to translate the fundamental findings into clinical practice. The corresponding gain of knowledge are the basis of the funding of biotech companies with which we are closely collaborating and help us obtain large sets of results and novel methods for the development of our present future in science.
Altogether, our laboratory is a consortium of unique expertise in the field of microbiology, immunology, heart, metabolic and gastrointestinal physiology, epidemiology and mathematics in order to translate from clinical observation towards molecular understanding and benefit in humans.
Identification of biomarkers causal to the diseases to predict, classify and diagnose diseases and co-morbidities.
Identification of functional targets and corresponding molecules suitable to the development of novel therapeutic strategies based on the control of intestinal functions.
European FP7: FLORINASH, Italy, Spain, Great Britain
Last updated December 2, 2014